AI Article Synopsis
- The study investigates drug resistance in leishmaniasis by evaluating the sensitivity of 36 patient isolates in French Guiana to seven different treatments.
- High variability was found in the isolates' response to the drugs, with one isolate showing high resistance levels.
- Pentamidine, the primary treatment, remained effective at low doses, correlating well with patient recovery outcomes at 94%.
Article Abstract
AbstractAnti-leishmaniasis drug resistance is a common problem worldwide. The aim of this study was to inventory the general in vitro level of sensitivity of isolates circulating in French Guiana and to highlight potential in vitro pentamidine-resistant isolates. This sensitivity study was conducted on 36 patient-promastigote isolates for seven drugs (amphotericin B, azithromycin, fluconazole, meglumine antimoniate, miltefosine, paromomycin, and pentamidine) using the Cell Counting Kit-8 viability test. The IC values obtained were heterogeneous. One isolate exhibited high IC values for almost all drugs tested. Pentamidine, which is the first-line treatment in French Guiana, showed efficacy at very low doses (mean of 0.0038 μg/mL). The concordance of the in vitro pentamidine results with the patients' clinical outcomes was 94% ( = 0.82).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417208 | PMC |
| http://dx.doi.org/10.4269/ajtmh.16-0373 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!